Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Posttraumatic Stress Disorder With Attention Defic
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Blood Pressure
Interventions: Provex CV, placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Insomnia
Interventions: Defined CBD, Placebo; Drug
Lead sponsor: Defined Research; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pediatric Bipolar Spectrum Disorders
Interventions: Omega-3, Inositol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 12 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Knee
Interventions: Fisetin, Placebo oral capsule; Dietary Supplement · Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 40 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: HIV Infection, Tuberculosis
Interventions: Strategy: Immediate ART, Strategy: Deferred ART; Other
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 13 Years and older
Enrollment: 809 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 46
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more

Conditions: Coronavirus Infections
Interventions: Opaganib, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 8
States / cities: Scottsdale, Arizona • Miami, Florida • Detroit, Michigan + 3 more

Conditions: Pain, Postoperative
Interventions: TiZANidine 2 MG Oral Capsule; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 25
States / cities: Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more

Conditions: Healthy
Interventions: Repaglinide, Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions: MEK162; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 18 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Refractory Hypertension
Interventions: Placebo, TC-5214; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bipolar I Disorder
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Springdale, Arkansas • Carson, California • Cerritos, California + 20 more

Conditions: Dietary Carcinogenesis
Interventions: ACCS100, Placebo; Drug
Lead sponsor: Texas Enterosorbents Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Meniscus Tear, Meniscus; Derangement, Meniscus Lesion, Meniscus Disorder
Interventions: Fisetin, Placebo oral capsule; Drug
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: ANCA-associated Vasculitis
Interventions: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Healthy Volunteers
Interventions: 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Methamphetamine-dependence
Interventions: Ibudilast, Placebo Oral Tablet; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Rheumatoid Arthritis (RA)
Interventions: Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 78
States / cities: Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more

Conditions: Smoking
Interventions: Cycloserine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Anxiety Disorders
Interventions: SSR149415, Placebo, Paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dyslipidemia
Interventions: Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more

Conditions: Hyperinsulinism-Hyperammonemia Syndrome
Interventions: Vitamin E; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Atomoxetine and Executive Function in PTSD

Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

Inositol and Omega-3 Fatty Acids in Pediatric Mania

Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Study of MEK162 for Children With Low-Grade Gliomas

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Vitamin E Efficacy in HI/HA